Cibus initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Cibus with a Buy rating and $25 price target. Cibus has emerged as an agricultural technology company specializing in developing and licensing productivity-enhancing plant traits to seed companies, with a strong emphasis on agricultural non-transgenic gene editing and creating sustainable low-carbon ingredients, the analyst tells investors in a research note. The firm says the company has a stronger technology and structural position post the merger with Calyxt.